Groupama Asset Managment Boosts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Groupama Asset Managment lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,017,191 shares of the company's stock after purchasing an additional 101,131 shares during the quarter. Groupama Asset Managment owned 0.64% of Ionis Pharmaceuticals worth $35,561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Signaturefd LLC raised its holdings in Ionis Pharmaceuticals by 160.0% in the fourth quarter. Signaturefd LLC now owns 949 shares of the company's stock worth $33,000 after buying an additional 584 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Ionis Pharmaceuticals by 183.8% during the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company's stock valued at $36,000 after acquiring an additional 671 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in Ionis Pharmaceuticals by 40.9% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company's stock worth $43,000 after acquiring an additional 314 shares during the last quarter. Quantbot Technologies LP bought a new position in Ionis Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Finally, Venturi Wealth Management LLC purchased a new stake in Ionis Pharmaceuticals during the 4th quarter valued at $107,000. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Price Performance

NASDAQ:IONS traded down $1.43 during trading hours on Friday, hitting $27.09. 2,292,741 shares of the stock traded hands, compared to its average volume of 1,474,437. The stock has a 50 day moving average price of $32.05 and a 200 day moving average price of $35.29. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The company has a market cap of $4.31 billion, a price-to-earnings ratio of -8.91 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a 1 year low of $26.88 and a 1 year high of $52.34.

Remove Ads

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. Ionis Pharmaceuticals's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.12 EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IONS shares. Redburn Atlantic began coverage on Ionis Pharmaceuticals in a report on Monday, March 31st. They set a "neutral" rating and a $39.00 price target on the stock. Guggenheim reiterated a "buy" rating on shares of Ionis Pharmaceuticals in a research note on Thursday. William Blair restated an "outperform" rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Citigroup dropped their target price on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, StockNews.com upgraded shares of Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $58.37.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 38,843 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total value of $1,229,380.95. Following the sale, the chief executive officer now owns 180,683 shares in the company, valued at $5,718,616.95. The trade was a 17.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Swayze sold 7,154 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $32.84, for a total transaction of $234,937.36. Following the transaction, the executive vice president now directly owns 45,670 shares of the company's stock, valued at $1,499,802.80. This trade represents a 13.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,956 shares of company stock valued at $3,608,439 over the last 90 days. Company insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.